Investors Face October Deadline in ARS Pharmaceuticals Securities Suit

The lawsuit, filed by the Rosen Law Firm, focuses on investors who purchased ARS Pharmaceuticals (NASDAQ: SPRY) securities between March 9 and June 24, 2026. Plaintiffs allege that the company misled the market by projecting that expanded insurance coverage with CVS Caremark would commence on July 1, 2026, in time for the peak allergy season. According to the complaint, these assurances were either false or omitted material adverse facts, resulting in artificially inflated stock prices before the true status of the coverage was revealed.

While a class action has been initiated, no class has been formally certified by the court. Investors are not currently represented by counsel unless they choose to retain an attorney. Participation as a lead plaintiff is optional, and those who purchased the stock during the specified period may also choose to remain absent class members. Interested parties can contact Phillip Kim at the Rosen Law Firm to review their options regarding the litigation and potential recovery.